Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis

American Journal of Hematology

Volumn 90, Issue 3, 2015, Pages 181-186

  Kaufman, Gregory P ^a   Dispenzieri, Angela ^a   Gertz, Morie A ^a   Lacy, Martha Q ^a   Buadi, Francis K ^a   Hayman, Suzanne R ^a   Leung, Nelson ^a   Dingli, David ^a   Lust, John A ^a   Lin, Yi ^a   Kapoor, Prashant ^a   Go, Ronald S ^a   Zeldenrust, Steven R ^a   Kyle, Robert A ^a   Rajkumar, S Vincent ^a   Kumar, Shaji K ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MELPHALAN; IMMUNOGLOBULIN LIGHT CHAIN; PROTEASOME INHIBITOR;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; FEMALE; HUMAN; KINETICS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NORMAL RATIO OF INVOLVED AND UNINVOLVED FREE LIGHT CHAIN RATIO; ORGAN; ORGAN RESPONSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AUTOTRANSPLANTATION; BLOOD; DRUG EFFECTS; DRUG MONITORING; HEART; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; KIDNEY; LIVER; MIDDLE AGED; MORTALITY; PATHOLOGY; PLASMA CELL; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; DEXAMETHASONE; DRUG MONITORING; FEMALE; HEART; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY; LIVER; MALE; MELPHALAN; MIDDLE AGED; PLASMA CELLS; PROTEASOME INHIBITORS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84923082032     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23898     Document Type: Article

References (26)

1. Kyle R, Gertz M. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
2. Gertz M. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:181-186.
3. Seldin D, Anderson J, Sanchorawala V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004;104:1888-1893.
4. th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-328.
5. Palladini G, Dispenzieri A, Gertz, M, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol. 2012;30:4541-4549.
6. Lebovic D, Hoffman J, Levine B, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008;143:369-373.
7. Kumar S, Dispenzieri A, Lacy M, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011;86;251-255.
8. Gertz M, Kyle R, Greipp P. Response rates and survival in primary systemic amyloidosis. Blood 1991;77:257-262.
9. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-1093.
10. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010;116:3426-3430.
11. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-3858.
12. Merlini G, Seldin D, Gertz M. Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924-1933.
13. Shi J, Guan J, Jiang B, Brenner D, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci 2010;107:4188-4193.
14. Merlini G, Palladini G. Amyloidosis: Is a cure possible? Annals of Oncol 2008;19:iv63-iv66.
15. Dispenzieri A, Gertz M, Kyle R, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751.
16. Dispenzieri A, Lacy M, Katzmann J, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantion. Blood 2006;107:3378-3383.
17. Cibeira M, Sanchorawala V, Seldin D, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients. Blood 2011;118:4346-4352.
18. Lachmann H, Gallimore R, Gillmore J, et al. Outcome in systemic AL amyloidosis in relation to change in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
19. Leung N, Dispenzieri A, Fervenza F, et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis 2005;46:270-277.
20. Gertz M, Leung N, Lacy M, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 2009;24:3132-3137.
21. Dember L, Sanchorawala V, Seldin D, et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 2001;1;134(9 Pt 1):746-753.
22. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351-1358.
23. Mikhael J, Schuster S, Jimenez-Zepeda V, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391-4394.
24. Bochtler T, Hegenbart U, Heiss C, et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood 2011;117:3809-3815.
25. Gertz M, Lacy M, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837-2840.
26. Dispenzieri A, Lacy M, Kyle R, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001;19:3350-3356.